Skip to main content
Erschienen in: Endocrine 2/2024

02.01.2024 | Original Article

Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves’ hyperthyroidism: a randomized trial and a risk-scoring model

verfasst von: Fereidoun Azizi, Atieh Amouzegar, Davood Khalili, Hengameh Abdi, Maryam Tohidi, Mehdi Hedayati, Leila Cheraghi, Yadollah Mehrabi, Miralireza Takyar

Erschienen in: Endocrine | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In Graves’ disease, administration of low-dose methimazole for more than 60 months induces higher remission rates compared with the conventional duration of 12–18 months. However, the risk of recurrence and its predictors beyond 48 months of drug withdrawal are not known. The aims of this study were to determine the risk of recurrence during 84 months after withdrawal of short- or long-term methimazole therapy and a risk stratification for recurrence of hyperthyroidism.

Methods

A total of 258 patients were treated with methimazole for a median of 18 months and randomized to discontinuation of the drug(conventional short-term group; n = 128) or continuation of the treatment up to 60–120 months(long-term group; n = 130). Patients were followed for 84 months after methimazole withdrawal. Cox proportional hazards modeling was performed to identify factors associated with relapse and develop a risk-scoring model at the time of discontinuing the treatment.

Results

Hyperthyroidism recurred in 67 of 120(56%) of conventionally-treated patients versus 20 of 118(17%) of those who received long-term methimazole treatment, p < 0.001. Age, sex, goiter grade, triiodothyronine, thyrotropin, and thyrotropin receptor antibodies were significant predictors of recurrence in both “conventional” and “long-term” groups but free thyroxine just in the “long-term” group. The risk-scoring model had a good discrimination power (optimism corrected c-index = 0.78,95%CI = 0.73–0.82) with a range of 0–14 and sensitivity of 86% and specificity of 62% at the risk-score of eight.

Conclusion

A relapse-free state was achieved in 83% of patients with Graves’ hyperthyroidism 84 months after cessation of long-term methimazole treatment which could be predicted by some significant predictors in a simple risk-scoring system.
Literatur
1.
Zurück zum Zitat J.P. Brito, S. Payne, N. Singh Ospina, R. Rodriguez-Gutierrez, S. Maraka, L.R. Sangaralingham, N.M. Iñiguez-Ariza, V.M. Montori, M.N. Stan, Patterns of use, efficacy, and safety of treatment options for patients with Graves’ disease: a nationwide population-based study. Thyroid 30(3), 357–364 (2020)CrossRefPubMed J.P. Brito, S. Payne, N. Singh Ospina, R. Rodriguez-Gutierrez, S. Maraka, L.R. Sangaralingham, N.M. Iñiguez-Ariza, V.M. Montori, M.N. Stan, Patterns of use, efficacy, and safety of treatment options for patients with Graves’ disease: a nationwide population-based study. Thyroid 30(3), 357–364 (2020)CrossRefPubMed
2.
Zurück zum Zitat C.M. van Kinschot, V.R. Soekhai, E.W. de Bekker-Grob, W.E. Visser, R.P. Peeters, T.M. van Ginhoven, C. van Noord, Preferences of patients and clinicians for treatment of Graves’ disease: a discrete choice experiment. Eur. J. Endocrinol. 184(6), 803–812 (2021)CrossRefPubMed C.M. van Kinschot, V.R. Soekhai, E.W. de Bekker-Grob, W.E. Visser, R.P. Peeters, T.M. van Ginhoven, C. van Noord, Preferences of patients and clinicians for treatment of Graves’ disease: a discrete choice experiment. Eur. J. Endocrinol. 184(6), 803–812 (2021)CrossRefPubMed
3.
Zurück zum Zitat F. Azizi, R. Malboosbaf, Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27(10), 1223–1231 (2017)CrossRefPubMed F. Azizi, R. Malboosbaf, Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27(10), 1223–1231 (2017)CrossRefPubMed
4.
Zurück zum Zitat F. Azizi, V. Yousefi, A. Bahrainian, F. Sheikholeslami, M. Tohidi, Y. Mehrabi, Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch. Iran. Med. 15(8), 0–0 (2012) F. Azizi, V. Yousefi, A. Bahrainian, F. Sheikholeslami, M. Tohidi, Y. Mehrabi, Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch. Iran. Med. 15(8), 0–0 (2012)
5.
Zurück zum Zitat O.M. El Kawkgi, D.S. Ross, M.N. Stan, Comparison of long‐term antithyroid drugs versus radioactive iodine or surgery for Graves’ disease: a review of the literature. Clin. Endocrinol. 95(1), 3–12 (2021)CrossRef O.M. El Kawkgi, D.S. Ross, M.N. Stan, Comparison of long‐term antithyroid drugs versus radioactive iodine or surgery for Graves’ disease: a review of the literature. Clin. Endocrinol. 95(1), 3–12 (2021)CrossRef
6.
Zurück zum Zitat D. Villagelin, J.H. Romaldini, R.B. Santos, A.B. Milkos, L.S. Ward, Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25(12), 1282–1290 (2015)CrossRefPubMed D. Villagelin, J.H. Romaldini, R.B. Santos, A.B. Milkos, L.S. Ward, Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25(12), 1282–1290 (2015)CrossRefPubMed
7.
Zurück zum Zitat F. Azizi, A. Amouzegar, M. Tohidi, M. Hedayati, D. Khalili, L. Cheraghi, Y. Mehrabi, M. Takyar, Increased remission rates after long-term methimazole therapy in patients with Graves’ disease: results of a randomized clinical trial. Thyroid 29(9), 1192–1200 (2019)CrossRefPubMed F. Azizi, A. Amouzegar, M. Tohidi, M. Hedayati, D. Khalili, L. Cheraghi, Y. Mehrabi, M. Takyar, Increased remission rates after long-term methimazole therapy in patients with Graves’ disease: results of a randomized clinical trial. Thyroid 29(9), 1192–1200 (2019)CrossRefPubMed
8.
Zurück zum Zitat G.J. Kahaly, L. Bartalena, L. Hegedüs, L. Leenhardt, K. Poppe, S.H. Pearce, 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur. Thyroid J. 7(4), 167–186 (2018)CrossRefPubMedPubMedCentral G.J. Kahaly, L. Bartalena, L. Hegedüs, L. Leenhardt, K. Poppe, S.H. Pearce, 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur. Thyroid J. 7(4), 167–186 (2018)CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10), 1343–1421 (2016)CrossRefPubMed D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26(10), 1343–1421 (2016)CrossRefPubMed
10.
Zurück zum Zitat F. Azizi, H. Abdi, A. Amouzegar, Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial. BMC Endocr. Disord. 21(1), 1–7 (2021)CrossRef F. Azizi, H. Abdi, A. Amouzegar, Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial. BMC Endocr. Disord. 21(1), 1–7 (2021)CrossRef
11.
Zurück zum Zitat T. Konishi, Y. Okamoto, M. Ueda, Y. Fukuda, I. Harusato, Y. Tsukamoto, N. Hamada, Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves’ disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr. J. 58(2), 95–100 (2011)CrossRefPubMed T. Konishi, Y. Okamoto, M. Ueda, Y. Fukuda, I. Harusato, Y. Tsukamoto, N. Hamada, Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves’ disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr. J. 58(2), 95–100 (2011)CrossRefPubMed
12.
Zurück zum Zitat D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, J. Lescouarch, J. Herry, H. Allannic, Antithyroid drugs and Graves’ disease—prospective randomized assessment of long‐term treatment. Clin. Endocrinol. 50(1), 127–132 (1999)CrossRef D. Maugendre, A. Gatel, L. Campion, C. Massart, I. Guilhem, Y. Lorcy, J. Lescouarch, J. Herry, H. Allannic, Antithyroid drugs and Graves’ disease—prospective randomized assessment of long‐term treatment. Clin. Endocrinol. 50(1), 127–132 (1999)CrossRef
13.
Zurück zum Zitat E. Mazza, M. Carlini, D. Flecchia, A. Blatto, O. Zuccarini, S. Gamba, S. Beninati, M. Messina, Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J. Endocrinol Investig. 31(10), 866–872 (2008)CrossRef E. Mazza, M. Carlini, D. Flecchia, A. Blatto, O. Zuccarini, S. Gamba, S. Beninati, M. Messina, Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J. Endocrinol Investig. 31(10), 866–872 (2008)CrossRef
14.
Zurück zum Zitat K. Shizume, M. Irie, S. Nagataki, F. Matsuzaki, Y. Shishiba, H. Suematsu, T. Tsushima, Long-term result of antithyroid drug therapy for Grave’s disease follow up after more than 5 years. Endocrinol Japonica 17(5), 327–332 (1970)CrossRef K. Shizume, M. Irie, S. Nagataki, F. Matsuzaki, Y. Shishiba, H. Suematsu, T. Tsushima, Long-term result of antithyroid drug therapy for Grave’s disease follow up after more than 5 years. Endocrinol Japonica 17(5), 327–332 (1970)CrossRef
15.
Zurück zum Zitat K. Okamura, S. Bandai, M. Fujikawa, K. Sato, H. Ikenoue, T. Kitazono, Long-term antithyroid drug treatment: Trends in serum TSH and TSH receptor antibody changes in patients with Graves' disease. Int. J. Endocrinol. Metab. 18(Suppl), e101139:1–8 (2020)CrossRef K. Okamura, S. Bandai, M. Fujikawa, K. Sato, H. Ikenoue, T. Kitazono, Long-term antithyroid drug treatment: Trends in serum TSH and TSH receptor antibody changes in patients with Graves' disease. Int. J. Endocrinol. Metab. 18(Suppl), e101139:1–8 (2020)CrossRef
16.
Zurück zum Zitat C. Perez, N.S. Scrimshaw, J. Munoz, Technique of endemic goitre surveys. Monogr. Ser. World Health Organ 44, 369–383 (1960)PubMed C. Perez, N.S. Scrimshaw, J. Munoz, Technique of endemic goitre surveys. Monogr. Ser. World Health Organ 44, 369–383 (1960)PubMed
17.
Zurück zum Zitat D. Hermsen, M. Broecker-Preuss, M. Casati, J.C. Mas, A. Eckstein, D. Gassner, J. van Helden, K. Inomata, J. Jarausch, J. Kratzsch, Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin. Chim. Acta 401(1-2), 84–89 (2009)CrossRef D. Hermsen, M. Broecker-Preuss, M. Casati, J.C. Mas, A. Eckstein, D. Gassner, J. van Helden, K. Inomata, J. Jarausch, J. Kratzsch, Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin. Chim. Acta 401(1-2), 84–89 (2009)CrossRef
18.
Zurück zum Zitat A. Amouzegar, H. Delshad, L. Mehran, M. Tohidi, F. Khafaji, F. Azizi, Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study. J. Endocrinol Investig. 36(11), 950–954 (2013) A. Amouzegar, H. Delshad, L. Mehran, M. Tohidi, F. Khafaji, F. Azizi, Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study. J. Endocrinol Investig. 36(11), 950–954 (2013)
19.
Zurück zum Zitat E. Piantanida, A. Lai, L. Sassi, D. Gallo, E. Spreafico, M. Tanda, L. Bartalena, Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm. Metab. Res. 47(10), 767–772 (2015)CrossRefPubMed E. Piantanida, A. Lai, L. Sassi, D. Gallo, E. Spreafico, M. Tanda, L. Bartalena, Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm. Metab. Res. 47(10), 767–772 (2015)CrossRefPubMed
20.
Zurück zum Zitat D.G. Kleinbaum, Epidemiologic methods: the “art” in the state of the art. J. Clin. Epidemiol. 55(12), 1196–1200 (2002)CrossRefPubMed D.G. Kleinbaum, Epidemiologic methods: the “art” in the state of the art. J. Clin. Epidemiol. 55(12), 1196–1200 (2002)CrossRefPubMed
21.
Zurück zum Zitat Steyerberg E.W.: Overfitting and optimism in prediction models. In: Clinical prediction models. Springer; 2019: 95-112. Steyerberg E.W.: Overfitting and optimism in prediction models. In: Clinical prediction models. Springer; 2019: 95-112.
22.
Zurück zum Zitat K.P. Burnham, D.R. Anderson, Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res. 33(2), 261–304 (2004)CrossRef K.P. Burnham, D.R. Anderson, Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res. 33(2), 261–304 (2004)CrossRef
23.
Zurück zum Zitat U. Feldt-Rasmussen, H. Schleusener, P. Carayon, Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J. Clin. Endocrinol. Metab. 78(1), 98–102 (1994)PubMed U. Feldt-Rasmussen, H. Schleusener, P. Carayon, Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J. Clin. Endocrinol. Metab. 78(1), 98–102 (1994)PubMed
24.
Zurück zum Zitat O. Törring, L. Tallstedt, G. Wallin, G. Lundell, J.-G. Ljunggren, A. Taube, M. Sääf, B. Hamberger, Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. Thyroid Study Group. J. Clin. Endocrinol. Metab. 81(8), 2986–2993 (1996)PubMed O. Törring, L. Tallstedt, G. Wallin, G. Lundell, J.-G. Ljunggren, A. Taube, M. Sääf, B. Hamberger, Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. Thyroid Study Group. J. Clin. Endocrinol. Metab. 81(8), 2986–2993 (1996)PubMed
25.
Zurück zum Zitat P.-W. Wang, Prediction of relapse after antithyroid drugs withdrawal: A narrative review. Int. J. Endocrinol. Metab. 18(Suppl), e102346:1–8 (2020)CrossRef P.-W. Wang, Prediction of relapse after antithyroid drugs withdrawal: A narrative review. Int. J. Endocrinol. Metab. 18(Suppl), e102346:1–8 (2020)CrossRef
26.
Zurück zum Zitat A.K. Eckstein, H. Lax, C. Lösch, D. Glowacka, M. Plicht, K. Mann, J. Esser, N.G. Morgenthaler, Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin. Endocrinol. 67(4), 607–612 (2007)CrossRef A.K. Eckstein, H. Lax, C. Lösch, D. Glowacka, M. Plicht, K. Mann, J. Esser, N.G. Morgenthaler, Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin. Endocrinol. 67(4), 607–612 (2007)CrossRef
27.
Zurück zum Zitat N.N.Z. Tun, G. Beckett, N.N. Zammitt, M.W. Strachan, J.R. Seckl, F.W. Gibb, Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves’ disease relapse. Thyroid 26(8), 1004–1009 (2016)CrossRefPubMed N.N.Z. Tun, G. Beckett, N.N. Zammitt, M.W. Strachan, J.R. Seckl, F.W. Gibb, Thyrotropin receptor antibody levels at diagnosis and after thionamide course predict Graves’ disease relapse. Thyroid 26(8), 1004–1009 (2016)CrossRefPubMed
28.
Zurück zum Zitat B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, O.E. Janssen, Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease. Thyroid 15(9), 1047–1054 (2005)CrossRefPubMed B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K. Mann, O.E. Janssen, Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease. Thyroid 15(9), 1047–1054 (2005)CrossRefPubMed
29.
Zurück zum Zitat C. Carella, G. Mazziotti, F. Sorvillo, M. Piscopo, M. Cioffi, P. Pilla, R. Nersita, S. Iorio, G. Amato, L. Braverman, Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16(3), 295–302 (2006)CrossRefPubMed C. Carella, G. Mazziotti, F. Sorvillo, M. Piscopo, M. Cioffi, P. Pilla, R. Nersita, S. Iorio, G. Amato, L. Braverman, Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 16(3), 295–302 (2006)CrossRefPubMed
30.
Zurück zum Zitat F. Azizi, Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid 30(10), 1451–1457 (2020)CrossRefPubMed F. Azizi, Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid 30(10), 1451–1457 (2020)CrossRefPubMed
31.
Zurück zum Zitat F. Azizi, H. Abdi, L. Mehran, A. Amouzegar, Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. J. Endocrinol. Investig. 45(6), 1139–1150 (2022)CrossRef F. Azizi, H. Abdi, L. Mehran, A. Amouzegar, Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. J. Endocrinol. Investig. 45(6), 1139–1150 (2022)CrossRef
32.
Zurück zum Zitat D.S. Cooper, Long-term antithyroid drug therapy. Curr. Opin. Endocrinol., Diabetes Obes. 28(5), 510–516 (2021)CrossRefPubMed D.S. Cooper, Long-term antithyroid drug therapy. Curr. Opin. Endocrinol., Diabetes Obes. 28(5), 510–516 (2021)CrossRefPubMed
33.
Zurück zum Zitat R. Malboosbaf, F. Azizi, Long-term treatment with antithyroid drugs: Efficacy and safety. Int. J. Endocrinol. Metab. 18(Suppl), e101487:1–10 (2020)CrossRef R. Malboosbaf, F. Azizi, Long-term treatment with antithyroid drugs: Efficacy and safety. Int. J. Endocrinol. Metab. 18(Suppl), e101487:1–10 (2020)CrossRef
34.
Zurück zum Zitat T. Struja, H. Fehlberg, A. Kutz, L. Guebelin, C. Degen, B. Mueller, P. Schuetz, Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur. J. Endocrinol. 176(1), 87–97 (2017)CrossRefPubMed T. Struja, H. Fehlberg, A. Kutz, L. Guebelin, C. Degen, B. Mueller, P. Schuetz, Can we predict relapse in Graves’ disease? Results from a systematic review and meta-analysis. Eur. J. Endocrinol. 176(1), 87–97 (2017)CrossRefPubMed
35.
Zurück zum Zitat X.G. Vos, E. Endert, A. Zwinderman, J.G. Tijssen, W.M. Wiersinga, Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 101(4), 1381–1389 (2016)CrossRefPubMed X.G. Vos, E. Endert, A. Zwinderman, J.G. Tijssen, W.M. Wiersinga, Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 101(4), 1381–1389 (2016)CrossRefPubMed
36.
Zurück zum Zitat M. Preus, M. Frecker, V. Stenszky, C. BALAŠS, N. Farid, A prognostic score for Graves’ disease. Clin. Endocrinol. 23(6), 653–661 (1985)CrossRef M. Preus, M. Frecker, V. Stenszky, C. BALAŠS, N. Farid, A prognostic score for Graves’ disease. Clin. Endocrinol. 23(6), 653–661 (1985)CrossRef
37.
Zurück zum Zitat A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C. Gough, J.A. Franklyn, Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 85(3), 1038–1042 (2000)PubMed A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C. Gough, J.A. Franklyn, Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab. 85(3), 1038–1042 (2000)PubMed
38.
Zurück zum Zitat P. Anagnostis, F. Adamidou, S.A. Polyzos, S. Katergari, E. Karathanasi, C. Zouli, A. Panagiotou, M. Kita, Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine 44(2), 448–453 (2013)CrossRefPubMed P. Anagnostis, F. Adamidou, S.A. Polyzos, S. Katergari, E. Karathanasi, C. Zouli, A. Panagiotou, M. Kita, Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine 44(2), 448–453 (2013)CrossRefPubMed
39.
Zurück zum Zitat E. Masiello, G. Veronesi, D. Gallo, P. Premoli, E. Bianconi, S. Rosetti, C. Cusini, J. Sabatino, S. Ippolito, E. Piantanida, Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J. Endocrinol Investig. 41(12), 1425–1432 (2018)CrossRef E. Masiello, G. Veronesi, D. Gallo, P. Premoli, E. Bianconi, S. Rosetti, C. Cusini, J. Sabatino, S. Ippolito, E. Piantanida, Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J. Endocrinol Investig. 41(12), 1425–1432 (2018)CrossRef
40.
Zurück zum Zitat T. Struja, M. Kaeslin, F. Boesiger, R. Jutzi, N. Imahorn, A. Kutz, L. Bernasconi, E. Mundwiler, B. Mueller, M. Christ-Crain et al. External validation of the GREAT score to predict relapse risk in Graves’ disease: results from a multicenter, retrospective study with 741 patients. Eur. J. Endocrinol. 176(4), 413–419 (2017)CrossRefPubMed T. Struja, M. Kaeslin, F. Boesiger, R. Jutzi, N. Imahorn, A. Kutz, L. Bernasconi, E. Mundwiler, B. Mueller, M. Christ-Crain et al. External validation of the GREAT score to predict relapse risk in Graves’ disease: results from a multicenter, retrospective study with 741 patients. Eur. J. Endocrinol. 176(4), 413–419 (2017)CrossRefPubMed
41.
Zurück zum Zitat S.S. Zuhur, G. Elbuken, I. Yildiz, P. Kadioglu, S. Erol, S. Sahin, F. Kilinc, G. Akbaba, B. Topcu, Y. Altuntas, External Validation of the GREAT Score in Turkish Patients with Graves’ Hyperthyroidism Treated with the Titration Regimen Method of Antithyroid Drugs: A Multicenter Study. Horm. Metab. Res. = Horm.- und Stoffwechselforschung = Hormones et. Metab. 51(10), 627–633 (2019)CrossRef S.S. Zuhur, G. Elbuken, I. Yildiz, P. Kadioglu, S. Erol, S. Sahin, F. Kilinc, G. Akbaba, B. Topcu, Y. Altuntas, External Validation of the GREAT Score in Turkish Patients with Graves’ Hyperthyroidism Treated with the Titration Regimen Method of Antithyroid Drugs: A Multicenter Study. Horm. Metab. Res. = Horm.- und Stoffwechselforschung = Hormones et. Metab. 51(10), 627–633 (2019)CrossRef
Metadaten
Titel
Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves’ hyperthyroidism: a randomized trial and a risk-scoring model
verfasst von
Fereidoun Azizi
Atieh Amouzegar
Davood Khalili
Hengameh Abdi
Maryam Tohidi
Mehdi Hedayati
Leila Cheraghi
Yadollah Mehrabi
Miralireza Takyar
Publikationsdatum
02.01.2024
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03656-5

Weitere Artikel der Ausgabe 2/2024

Endocrine 2/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.